NCT02062632View on ClinicalTrials.gov

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 14, 2014

Primary Completion Date

May 29, 2015

Study Completion Date

November 6, 2017

Conditions
Esophageal CarcinomaHypopharyngeal CarcinomaLaryngeal CarcinomaLymphomaMesotheliomaMetastatic Malignant Neoplasm in the LungMetastatic Malignant Neoplasm in the PleuraMetastatic Malignant Neoplasm in the Spinal CordNon-Small Cell Lung CarcinomaSarcomaSmall Cell Lung CarcinomaThymic CarcinomaThymomaThyroid Gland Carcinoma
Interventions
DRUG

Doxepin Hydrochloride

Given orally

OTHER

Placebo

Given orally

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

54303

Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay

55905

Mayo Clinic, Rochester

68198

University of Nebraska Medical Center, Omaha

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER